Suven Life Sciences has received four product patents in Australia and New Zealand for its new chemical entities (NCEs), which could be used for treating various central nervous disorders.
which has an estimated $30 billion market potential globally
which has an estimated $30 billion market potential globally
0 comments:
Post a Comment